Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology

Mark J. Osborn, Beau R. Webber, Ronald T. McElmurry, Kyle D. Rudser, Anthony P. DeFeo, Michael Muradian, Anna Petryk, Benedikt Hallgrimsson, Bruce R. Blazar, Jakub Tolar, Elizabeth A. Braunlin

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Mucopolysaccharidosis type I (MPS IH) is a lysosomal storage disease (LSD) caused by inactivating mutations to the alpha-L-iduronidase (IDUA) gene. Treatment focuses on IDUA enzyme replacement and currently employed methods can be non-uniform in their efficacy particularly for the cardiac and craniofacial pathology. Therefore, we undertook efforts to better define the pathological cascade accounting for treatment refractory manifestations and demonstrate a role for the renin angiotensin system (RAS) using the IDUA−/− mouse model. Perturbation of the RAS in the aorta was more profound in male animals suggesting a causative role in the observed gender dimorphism and angiotensin receptor blockade (ARB) resulted in improved cardiac function. Further, we show the ability of losartan to prevent shortening of the snout, a common craniofacial anomaly in IDUA−/− mice. These data show a key role for the RAS in MPS associated pathology and support the inclusion of losartan as an augmentation to current therapies.

Original languageEnglish (US)
Pages (from-to)281-289
Number of pages9
JournalJournal of Inherited Metabolic Disease
Volume40
Issue number2
DOIs
StatePublished - Mar 1 2017

Bibliographical note

Publisher Copyright:
© 2016, SSIEM.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

Fingerprint

Dive into the research topics of 'Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology'. Together they form a unique fingerprint.

Cite this